Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clover Health Investments (CLOV – Research Report), Cogent Biosciences (COGT – Research Report) and Adaptive Biotechnologies (ADPT – Research Report).
Clover Health Investments (CLOV)
Citi analyst Jason Cassorla maintained a Hold rating on Clover Health Investments yesterday and set a price target of $1.00. The company’s shares closed last Tuesday at $0.74, close to its 52-week low of $0.61.
According to TipRanks.com, Cassorla is a 1-star analyst with an average return of
Currently, the analyst consensus on Clover Health Investments is a Moderate Buy with an average price target of $1.33.
See the top stocks recommended by analysts >>
Cogent Biosciences (COGT)
Citi analyst David Lebovitz maintained a Buy rating on Cogent Biosciences today and set a price target of $13.00. The company’s shares closed last Tuesday at $7.76.
According to TipRanks.com, Lebovitz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Cogent Biosciences is a Strong Buy with an average price target of $15.44, which is a 108.9% upside from current levels. In a report issued on April 29, LifeSci Capital also maintained a Buy rating on the stock with a $16.00 price target.
Adaptive Biotechnologies (ADPT)
In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Buy rating on Adaptive Biotechnologies, with a price target of $5.00. The company’s shares closed last Tuesday at $3.11, close to its 52-week low of $2.28.
According to TipRanks.com, Vatnsdal ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Adaptive Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $6.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLOV:
- Clover Health Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Clover Health to Report First Quarter 2024 Financial Results on May 7, 2024
- Clover Health Appoints Peter Kuipers as New CFO
- Clover Health appoints Peter Kuipers as CFO
- Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
